After AIDS Clinical Trial 076

The changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants

Ellen R. Cooper, Robert P. Nugent, Clemente Diaz, Jane Pitt, Celine Hanson, Leslie A. Kalish, Hermann Mendez, Carmen Zorrilla, Ronald Hershow, John Moye, Vincent Smeriglio, Mary Glenn Fowler

Research output: Contribution to journalArticle

Abstract

To determine the impact of the AIDS Clinical Trials Group (ACTG) Protocol 076 results on the subsequent use of zidovudine during pregnancy and the transmission rate of human immunodeficiency virus (HIV) in a cohort of mother-infant pairs (Women and Infants Transmission Study), a retrospective analysis was done. Transmission rates were calculated by simple proportion for infants with at least 6 months of follow-up, stratified by date of birth (n = 453 born on or before 1 March 1994; n = 103 born after 1 March 1994). Transmission rates decreased from 19% to 8% (P = .005, Fisher's exact test). Zidovudine use increased during pregnancy (22% vs. 89%) and in newborns (1% vs. 79%). Both cohorts were similar with respect to maternal immunosuppression, mode of delivery, and demographics. In summary, in a perinatal HIV observational study, the release of results of ACTG Protocol 076 was associated with an increase in zidovudine use during pregnancy and a concomitant decline in HIV transmission from mothers to infants.

Original languageEnglish (US)
Pages (from-to)1207-1211
Number of pages5
JournalJournal of Infectious Diseases
Volume174
Issue number6
StatePublished - 1996
Externally publishedYes

Fingerprint

Zidovudine
Acquired Immunodeficiency Syndrome
Clinical Trials
HIV
Pregnancy
Mothers
Clinical Protocols
Pregnancy Rate
Immunosuppression
Observational Studies
Retrospective Studies
Demography
Parturition
Newborn Infant

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

After AIDS Clinical Trial 076 : The changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. / Cooper, Ellen R.; Nugent, Robert P.; Diaz, Clemente; Pitt, Jane; Hanson, Celine; Kalish, Leslie A.; Mendez, Hermann; Zorrilla, Carmen; Hershow, Ronald; Moye, John; Smeriglio, Vincent; Fowler, Mary Glenn.

In: Journal of Infectious Diseases, Vol. 174, No. 6, 1996, p. 1207-1211.

Research output: Contribution to journalArticle

Cooper, Ellen R. ; Nugent, Robert P. ; Diaz, Clemente ; Pitt, Jane ; Hanson, Celine ; Kalish, Leslie A. ; Mendez, Hermann ; Zorrilla, Carmen ; Hershow, Ronald ; Moye, John ; Smeriglio, Vincent ; Fowler, Mary Glenn. / After AIDS Clinical Trial 076 : The changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. In: Journal of Infectious Diseases. 1996 ; Vol. 174, No. 6. pp. 1207-1211.
@article{2c72103ea9994296bc9bc66be88444e4,
title = "After AIDS Clinical Trial 076: The changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants",
abstract = "To determine the impact of the AIDS Clinical Trials Group (ACTG) Protocol 076 results on the subsequent use of zidovudine during pregnancy and the transmission rate of human immunodeficiency virus (HIV) in a cohort of mother-infant pairs (Women and Infants Transmission Study), a retrospective analysis was done. Transmission rates were calculated by simple proportion for infants with at least 6 months of follow-up, stratified by date of birth (n = 453 born on or before 1 March 1994; n = 103 born after 1 March 1994). Transmission rates decreased from 19{\%} to 8{\%} (P = .005, Fisher's exact test). Zidovudine use increased during pregnancy (22{\%} vs. 89{\%}) and in newborns (1{\%} vs. 79{\%}). Both cohorts were similar with respect to maternal immunosuppression, mode of delivery, and demographics. In summary, in a perinatal HIV observational study, the release of results of ACTG Protocol 076 was associated with an increase in zidovudine use during pregnancy and a concomitant decline in HIV transmission from mothers to infants.",
author = "Cooper, {Ellen R.} and Nugent, {Robert P.} and Clemente Diaz and Jane Pitt and Celine Hanson and Kalish, {Leslie A.} and Hermann Mendez and Carmen Zorrilla and Ronald Hershow and John Moye and Vincent Smeriglio and Fowler, {Mary Glenn}",
year = "1996",
language = "English (US)",
volume = "174",
pages = "1207--1211",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - After AIDS Clinical Trial 076

T2 - The changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants

AU - Cooper, Ellen R.

AU - Nugent, Robert P.

AU - Diaz, Clemente

AU - Pitt, Jane

AU - Hanson, Celine

AU - Kalish, Leslie A.

AU - Mendez, Hermann

AU - Zorrilla, Carmen

AU - Hershow, Ronald

AU - Moye, John

AU - Smeriglio, Vincent

AU - Fowler, Mary Glenn

PY - 1996

Y1 - 1996

N2 - To determine the impact of the AIDS Clinical Trials Group (ACTG) Protocol 076 results on the subsequent use of zidovudine during pregnancy and the transmission rate of human immunodeficiency virus (HIV) in a cohort of mother-infant pairs (Women and Infants Transmission Study), a retrospective analysis was done. Transmission rates were calculated by simple proportion for infants with at least 6 months of follow-up, stratified by date of birth (n = 453 born on or before 1 March 1994; n = 103 born after 1 March 1994). Transmission rates decreased from 19% to 8% (P = .005, Fisher's exact test). Zidovudine use increased during pregnancy (22% vs. 89%) and in newborns (1% vs. 79%). Both cohorts were similar with respect to maternal immunosuppression, mode of delivery, and demographics. In summary, in a perinatal HIV observational study, the release of results of ACTG Protocol 076 was associated with an increase in zidovudine use during pregnancy and a concomitant decline in HIV transmission from mothers to infants.

AB - To determine the impact of the AIDS Clinical Trials Group (ACTG) Protocol 076 results on the subsequent use of zidovudine during pregnancy and the transmission rate of human immunodeficiency virus (HIV) in a cohort of mother-infant pairs (Women and Infants Transmission Study), a retrospective analysis was done. Transmission rates were calculated by simple proportion for infants with at least 6 months of follow-up, stratified by date of birth (n = 453 born on or before 1 March 1994; n = 103 born after 1 March 1994). Transmission rates decreased from 19% to 8% (P = .005, Fisher's exact test). Zidovudine use increased during pregnancy (22% vs. 89%) and in newborns (1% vs. 79%). Both cohorts were similar with respect to maternal immunosuppression, mode of delivery, and demographics. In summary, in a perinatal HIV observational study, the release of results of ACTG Protocol 076 was associated with an increase in zidovudine use during pregnancy and a concomitant decline in HIV transmission from mothers to infants.

UR - http://www.scopus.com/inward/record.url?scp=19244364987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19244364987&partnerID=8YFLogxK

M3 - Article

VL - 174

SP - 1207

EP - 1211

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 6

ER -